National policy of Ukraine on Rare (Orphan) Diseases
Abstract
According to the Ministry of Health of Ukraine, 80% of patients with rare diseases in Ukraine die within 5 years due to the lack of systematic diagnosis and qualified treatment. This is more than, for example, 50% in France. As Russia’s military incursion continues to disrupt basic health services, major efforts are needed to restore and strengthen health services, including access to medicines and medical equipment.
Under these circumstances, the heroic work of doctors, both on the territory of our country and abroad, who, despite the challenges faced by the community of rare diseases in Ukraine, did not stop for a moment their work to support and help the community of patients with rare diseases and the mobilization of political advocacy and legislation at the national level.
Currently, humanitarian organizations and the international community are making maximum efforts to generally protect the most vulnerable segment of the population, which is affected by the conflict, cannot leave and does not have access to humanitarian aid. The current situation should not undermine the reality that the needs of people living with a rare disease are real, enormous and unmet.
The creation of legal, economic and administrative mechanisms for the realization of the constitutional rights of the population of Ukraine suffering from rare (orphan) diseases, preservation and strengthening of their health, extension of the period of active longevity and length of their lives is one of the main tasks of the state.
So, the article proposes a structured complex political program document aimed at solving the issues of patients suffering from rare (orphan) diseases. During the development and formation of this state policy, the best practices of developed European countries were used. An overview of the state and problems of national regulatory and organizational support in the field of access to treatment for patients with rare (orphan) diseases was also conducted. Scientific achievements of domestic and foreign researchers, statistical data of state authorities, international organizations and own author’s research were taken into account.
Downloads
References
Zakon Ukrayiny` «Pro derzhavni finansovi garantiyi medy`chnogo obslugovuvannya naselennya» (Vidomosti Verxovnoyi Rady` (VVR), 2018, # 5, st.31) [Elektronnyj resurs]. – Rezhym dostupu: https://zakon.rada.gov.ua/laws/show/2168-19#Text [in Ukrainian].
Poyasnyuval`na zapy`ska do proyektu Postanovy` Kabinetu ministriv Ukrayiny` «Pro vnesennya zmin do punktu 8 Poryadku vy`znachennya rozmiru reimbursaciyi likars`ky`x zasobiv» 24-02/46/99-21vid 16.04.2021 [Elektronnyj resurs]. – Rezhym dostupu : dokument-2971_0_1_19-21.pdf (drs.gov.ua) [in Ukrainian].
Rozporyadzhennya Kabinetu ministriv Ukrayiny` vid 28 kvitnya 2021 r. # 377-r «Pro sxvalennya Koncepciyi rozvy`tku sy`stemy` nadannya medy`chnoyi dopomogy` gromadyanam, yaki strazhdayut` na ridkisni (orfanni) zaxvoryuvannya, na 2021–2026 roky`» [Elektronnyj resurs]. – Rezhym dostupu: https://www.apteka.ua/article/593338 [in Ukrainian].
Zakon Ukrayiny` pro vnesennya zmin do osnov zakonodavstva Ukrayiny` «Pro oxoronu zdorov’ya shhodo zabezpechennya profilakty`ky` ta likuvannya ridkisny`x (orfanny`x) zaxvoryuvan`» (Vidomosti Verxovnoyi Rady` (VVR), 2014, # 26, st.894) [Elektronnyj resurs]. – Rezhym dostupu: https://zakon.rada.gov.ua/laws/show/1213-18#Text [in Ukrainian].
Zakon Ukrayiny` Zakonoproekt shhodo vnesennya zmin do osnov zakonodavstva Ukrayiny` «Pro oxoronu zdorov’ya» # 11 (882) 18 Bereznya 2013 r. [Elektronnyj resurs]. – Rezhym dostupu : https://www.apteka.ua/article/217621 [in Ukrainian].
Rozporyadzhennya Kabinetu ministriv Ukrayiny` vid 30 ly`stopada 2016 r. # 1013-r «Pro sxvalennya Koncepciyi reformy` finansuvannya sy`stemy` oxorony` zdorov’ya» [Elektronnyj resurs]. – Rezhym dostupu : https://www.kmu.gov.ua/npas/249626689 [in Ukrainian].
Polity`chna propozy`ciya shhodo sxvalennya Koncepciyi rozvy`tku sy`stemy` nadannya dopomogy` gromadyanam, shho strazhdayut` na ridkisni (orfanni) zaxvoryuvannya na 2020 – 2025 roky` [Elektronnyj resurs]. – Rezhym dostupu : https://acp.moz.gov.ua/uploads/ckeditor/%D0%93%D1%80%D0%BE%D0%BC%D0%B0%D0%B4%D1%81%D1%8C%D0%BA%D0%B5%20%D0%BE%D0%B1%D0%B3%D0%BE%D0%B2%D0%BE%D1%80%D0%B5%D0%BD%D0%BD%D1%8F/2020/11/12/01/%D0%9F%D0%9E%D0%9B%D0%86%D0%A2%D0%98%D0%A7%D0%9D%D0%90%20%D0%9F%D0%A0%D0%9E%D0%9F%D0%9E%D0%97%D0%98%D0%A6%D0%86%D0%AF.pdf [in Ukrainian].
Ridkisni (orfanni) zaxvoryuvannya: yak zabezpechy`ty` paciyentiv likuvannyam? [Elektronnyj resurs]. – Rezhym dostupu : http://te.gov.ua/tepebovlyanska/ua/news/print/190666.htm [in Ukrainian].
Postanova Kabinetu ministriv Ukrayiny` vid 5 grudnya 2018 r. # 1022 shhodo zatverdzhennya «Derzhavnoyi strategiyi realizaciyi derzhavnoyi polity`ky` zabezpechennya naselennya likars`ky`my` zasobamy` na period do 2025 roku» [Elektronnyj resurs]. – Rezhym dostupu : https://www.apteka.ua/article/482099 [in Ukrainian].
Zvit pro upravlinnya derzhavnogo pidpry`yemstva «Derzhavny`j ekspertny`j centr Ministerstva oxorony` zdorov’ya Ukrayiny`» za 2020 rik [Elektronnyj resurs]. – Rezhym dostupu : https://www.dec.gov.ua/wp-content/uploads/2021/03/1614767343306131.pdf [in Ukrainian].
Polozhennya pro Ministerstvo oxorony` zdorov’ya Ukrayiny` [Elektronnyj resurs]. – Rezhym dostupu : https://www.kmu.gov.ua/npas/53786660 [in Ukrainian].
Schey, C., Krabbe, P.F.M., Postma, M.J. et al. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs. Orphanet J Rare Dis 12, 10 (2017). Accessible at: https://ojrd.biomedcentral.com/articles/10.1186/s13023-016-0555-3
Baran-Kooiker A, Czech M, Kooiker C. Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?. Front Public Health. 2018. Accessible at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197072/
Multi-criteria decision analysis to support HTA agencies – benefits, limitations and the way forward. / Baltussen, Rob; Marsh, K; Thokala, Praveen; Diaby, V; Cleemput, I; Garau, M.; Iskrov, G; Olyaeemanesh, A; Mirelman, Andrew; Mobinizadeh, M; Morton, Alec; Tringali, M; van Til, J; Valentim, J; Wagner, M; Youngkong, Sitaporn; Zah, Vladimir; Toll, A; Jansen, M; Bijlmakers, M J; Oortwijn, W; Broekhuizen, B. In: Value in Health, Vol. 22, No. 11, 15.10.2019, p. 1283–1288. Accessible at: https://strathprints.strath.ac.uk/68608/7/Baltussen_etal_ViH2019_Multi_criteria_decision_analysis_to_support_HTA_agencies.pdf
Statement for Rare Disease Day by Dr Tedros Adhanom Ghebreyesus, WHO Director-General. February 2018. Accessible at: https://www.who.int/mediacentre/news/statements/2018/rare-disease-day/en/
What does it mean to leave no one behind? A UNDP discussion paper and framework for implementation July 2018. Accessible at: https://www.undp.org/content/undp/en/home/librarypage/poverty-reduction/what-does-it-mean-to-leave-no-one-behind-.html.
Ukaz Prezy`denta Ukrayiny` #722/2019 vid 30 veresnya 2019 roku «Pro Cili stalogo rozvy`tku Ukrayiny` na period do 2030 roku» [Elektronnyj resurs]. – Rezhym dostupu : https://www.president.gov.ua/documents/7222019-29825 [in Ukrainian].
How to develop and implement a national drug policy. January 2003, World Health Organization. Accessible at: https://apps.who.int/medicinedocs/pdf/s4869e/s4869e.pdf)
Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe’s challenges, Brussels, 11.11.2008 COM(2008) 679 final . Accessible at: https://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf
Council Recommendation of 8 June 2009 on an Action in the Field of Rare Diseases (2009/C 151/02). Accessible at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32009H0703%2802%29
Overview Report on the State of the Art of Rare Disease Activities in Europe 2018 Version RD-ACTION WP6 Output. Accessible at: http://www.rd-action.eu/wp-content/uploads/2018/09/Final-Overview-Report-State-of-the-Art-2018-version.pdf
The European Project for Rare Diseases National Plans Development (EUROPLAN). Accessible at: http://www.europlanproject.eu/NationalPlans?idMap=1
A compilation of national plans, policies and government actions for rare diseases in 23 countries. Accessible at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290840/
Dharssi S., Wong-Rieger D., Harold M., Terry S. Review of 11 national policies for rare diseases in the context of key patient needs. Orphanet J Rare Dis. 2017 Mar 31. Accessible at: https://www.ncbi.nlm.nih.gov/pubmed/28359278
Komitet z py`tan` zdorov’ya naciyi, medy`chnoyi dopomogy` ta medy`chnogo straxuvannya napracyuvav rekomendaciyi shhodo vy`rishennya problem u sferi nadannya medy`chnoyi dopomogy` xvory`m na ridkisni (orfanni) zaxvoryuvannya. Informacijne upravlinnya Aparatu Verxovnoyi Rady` Ukrayiny`, opublikovano 21 zhovtnya 2019 [Elektronnyj resurs]. – Rezhym dostupu : https://rada.gov.ua/news/news_kom/183160.html [in Ukrainian].
The UK Strategy for Rare Diseases 2019 update to the Implementation Plan for England. Accessible at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/781472/2019-update-to-the-rare-diseases-implementation-plan-for-england.pdf
French National Plan for Rare Diseases 2018-2022 Sharing innovation, a diagnosis and a treatment. Accessible at: https://solidarites-sante.gouv.fr/IMG/pdf/pnmr3_-_en.pdf
Yak zabezpechy`ty` likuvannyam paciyentiv z orfanny`my` zaxvoryuvannyamy`: Pres-centr Ukrayins`kogo kry`zovogo media-centru: 10.10.2019 [Elektronnyj resurs]. – Rezhym dostupu : https://uacrisis.org/uk/73567-orphan-diseases [in Ukrainian].
Dlya chogo potriben neonatal`ny`j skry`ning? 24.10.2018 [Elektronnyj resurs]. – Rezhym dostupu : http://www.mvk.if.ua/profzahv/48838 [in Ukrainian].
Council Recommendation of 8 June 2009 on an Action in the Field of Rare Diseases, 2009/C 151/02. Accessible at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32009H0703%2802%29
Commission Decision of 30 November 2009 establishing a European Union Committee of Experts on Rare Diseases, 2009/872/EC, Accessible at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32009D0872
EUCERD Recommendations on Rare Disease Patient Registration and Data Collection (5 June 2013). Accessible at: http://www.eucerd.eu/wp-content/uploads/2013/06/EUCERD_Recommendations_RDRegistryDataCollection_adopted.pdf
Glossary of HTA Adaptation Terms, november 2007 [Електронний ресурс]. – Режим доступу : https://www.eunethta.eu/wp-content/uploads/2018/01/Glossary-of-HTA-Adaptation-Terms.pdf
Dostup k novыm lekarstvennыm sredstvam v Evrope: Texny`chesky`j doklad o poly`ty`chesky`x y`ny`cy`aty`vax y` vozmozhnostyax dlya sotrudny`chestva y` y`ssledovany`j [Elektronnyj resurs]. – Rezhym dostupu : http://www.euro.who.int/__data/assets/pdf_file/0011/292844/Access-new-medicines-TR-PIO-collaboration-research-ru.pdf?ua=1 [in Ukrainian].
Dostup k osnovnыm lekarstvennыm sredstvam, vakcy`nam y` medy`cy`nsky`m texnology`yam, Vsemy`rnaya organy`zacy`ya zdravooxraneny`ya, 2018 g. [Elektronnyj resurs]. – Rezhym dostupu : https://www.euro.who.int/__data/assets/pdf_file/0007/376477/fact-sheet-sdg-essential-medicines-rus.pdf [in Ukrainian].
Simoens, S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 6, 42 (2011) Accessible at: https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-6-42
WHO. Accessible at: https://www.who.int/medicines/technical_briefing/tbs/TBS2016_Pricing_Policies.pdf
Zamora, B., Maignen, F., O’Neill, P. et al. Comparing access to orphan medicinal products in Europe. Orphanet J Rare Dis 14, 95 (2019). Accessible at: https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1078-5
Orphan Medicines in Europe Are they really breaking the bank? 2019 Accessible at: http://download2.eurordis.org.s3.amazonaws.com/symposium/2019/Presentations/Breakout_3_Angela_McFarlane.pdf
Katherine Eve Young, Imen Soussi, Michiel Hemels & Mondher Toumi (2017) A comparative study of orphan drug prices in Europe, Journal of Market Access & Health Policy, Accessible at: https://www.tandfonline.com/doi/full/10.1080/20016689.2017.1297886
Policies for Orphan Diseases and Orphan Drugs KCE reports 112C, 2009. Accessible at: https://ec.europa.eu/health/ph_threats/non_com/docs/policies_orphan_en.pdf
Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers. Ollendorf DA(1), Chapman RH(2), Pearson SD(2).Accessible at: https://icer-review.org/wp-content/uploads/2019/09/Ollendorf-2018_Rare-Conditions.pdf
Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment. Malinowski Krzysztof Piotr, Kawalec Paweł, Trabka Wojciech, Sowada Christoph, Pilc Andrzej. Accessible at: https://www.frontiersin.org/articles/10.3389/fphar.2018.01263/full
«Bozhevil`na» yevropejs`ka sy`stema cinoutvorennya na orfanni liky` maye zakinchy`ty`sya. 29.07.2016 roku [Elektronnyj resurs]. – Rezhym dostupu : https://pink.pharmaintelligence.informa.com/PS118869/Crazy-European-Orphan-Drug-Pricing-System-Has-To-End [in Ukrainian].
BENELUXA: First results of multi-country cooperation on medicine price negotiations. Reflection Paper, September 2017. Accessible at: https://epha.org/wp-content/uploads/2017/10/EPHA-Reflection-Paper-Beneluxa-A2M.pdf
Luyidzhi van den Born Novy`j prory`v u peregovorax navkolo orfanny`x likiv, 23 chervnya 2016 roku [Elektronnyj resurs]. – Rezhym dostupu : https://qbd.eu/en/news/new-breakthrough-in-negotiations-around-orphan-drugs/ [in Ukrainian].
Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Accessible at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32000R0141
Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products Accessible at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A31993R2309
FDA Guidance Documents [Електронний ресурс]. – Режим доступу : https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products
The European Medicines Agency [Електронний ресурс]. – Режим доступу : https://www.ema.europa.eu/en/documents/other/fee-reductions-designated-orphan-medicinal-products_en.pdf
The European Medicines Agency [Електронний ресурс]. – Режим доступу : https://www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation/orphan-incentives
EURORDIS-Rare Diseases Europe [Електронний ресурс]. – Режим доступу : https://www.eurordis.org/content/promoting-orphan-drug-development
EMA. Orphan medicines figures 2000- 2018. Accessible at: https://www.ema.europa.eu/en/documents/other/orphan-medicines-figures-2000-2018_en.pdf
Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS One. 2015. Accessible at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599885/
FDA Guidance Documents [Електронний ресурс]. – Режим доступу : https://www.fda.gov/industry/developing-products-rare-diseases-conditions/orphan-products-clinical-trials-grants-program
Priority medicines for Europe and the World 2013 update. W Kaplan, VJ Wirtz, A Mantel-Teeuwisse. Organización Mundial de la Salud. Universiteit Utrecht. Accessible at: https://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf
Copyright (c) 2023 Ірина Живило
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
